Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 19/20 | 0.59 |
| ▸ | LOX | P28300 | 12/20 | 0.59 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30931700 | 0.82 | LOXL2 (0.62) | LOXL2LOXLOXL3 | |
| SCHEMBL4934891 | 0.81 | LOXL2 (0.67) | LOXL2LOXLOXL3 | |
| SCHEMBL4343502 | 0.77 | LOXL2 (0.56) | LOXL2LOXLOXL3 | |
| SCHEMBL4933505 | 0.77 | LOXL2 (0.70) | LOXL2LOXLOXL3 | |
| Hydrochloric Acid SCHEMBL30931587 | 0.76 | LOXL2 (0.54) | LOXL2LOXLOXL3 | |
| Hydrochloric Acid SCHEMBL13570541 | 0.76 | LOXL2 (0.54) | LOXL2LOXLOXL3 | |
| SCHEMBL29104571 | 0.76 | LOXL2 (0.54) | LOXL2LOXLOXL3 | |
| SCHEMBL429686 | 0.75 | LOXL2 (0.54) | LOXL2LOXLOXL3 | |
| SCHEMBL4934020 | 0.75 | LOXL2 (0.56) | LOXL2LOXLOXL3 | |
| SCHEMBL449200 | 0.74 | LOXL2 (1.00) | LOXL2LOXLOXL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063673-A1 | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors | JOHNSON ADAM RICHARD (US) | 2004-04-01 | — | — | US | claimed |
| WO-2004014384-A2 | CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-20040063673-A1 | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors | JOHNSON ADAM RICHARD (US) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063673-A1 | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors | MMP13, MMP1, MMP11 | LOXL2 249/4885LOX 395/4885LOXL3 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.